218 related articles for article (PubMed ID: 16988184)
1. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.
Segerström L; Fuchs D; Bäckman U; Holmquist K; Christofferson R; Azarbayjani F
Pediatr Res; 2006 Nov; 60(5):576-81. PubMed ID: 16988184
[TBL] [Abstract][Full Text] [Related]
2. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
3. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
5. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
7. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth.
Streck CJ; Zhang Y; Zhou J; Ng C; Nathwani AC; Davidoff AM
J Pediatr Surg; 2005 Jan; 40(1):236-43. PubMed ID: 15868591
[TBL] [Abstract][Full Text] [Related]
10. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
13. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
[TBL] [Abstract][Full Text] [Related]
14. High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts.
Joseph JM; Bouquet C; Opolon P; Morizet J; Aubert G; Rössler J; Gross N; Griscelli F; Perricaudet M; Vassal G
Cancer Gene Ther; 2003 Nov; 10(11):859-66. PubMed ID: 14605672
[TBL] [Abstract][Full Text] [Related]
15. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
16. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
17. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA
Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688
[TBL] [Abstract][Full Text] [Related]
19. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
20. Interaction between bevacizumab and murine VEGF-A: a reassessment.
Yu L; Wu X; Cheng Z; Lee CV; LeCouter J; Campa C; Fuh G; Lowman H; Ferrara N
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):522-7. PubMed ID: 18234994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
